Examining Recent Updates in ROS1+ NSCLC

Investigators hope to add a treatment option that has the potential to produce superior efficacy vs present ROS1 inhibitors for patients with ROS1+ NSCLC.

Stephen V. Liu, MD, discusses updated data from the phase 2 TRUST-II trial investigating taletrectinib in ROS1-positive non–small cell lung cancer.

Tony S. K. Mok, BMSc, MD, FASCO, discusses efficacy findings from a pooled analysis of the TRUST-I and TRUST-II trials of taletrectinib in ROS1+ NSCLC.

Jyoti Patel, MD, discusses the implications of the TRUST-II trial in locally advanced or metastatic ROS1-positive NSCLC, regardless of prior TKI exposure.

Alexander Drilon, MD, discusses efficacy findings from the TRUST-I and TRUST-II trials in patients with ROS1+ non–small cell lung cancer.

Taletrectinib elicited high and durable overall response rates with favorable tolerability in patients with advanced ROS1-positive NSCLC.

Taletrectinib was safe and generated durable responses in both TKI-naive and -pretreated patients with ROS1-positive non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses updated efficacy data from the TRUST-I study of taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Jessica Lin, MD, discusses key findings from the phase 2 TRUST-I trial in patients with ROS1 fusion–positive NSCLC.

Taletrectinib demonstrated high response rates and a tolerable safety profile in patients with ROS1-positive non–small cell lung cancer.